EICHORCondition: Plaque Psoriasis · Sponsor: Takeda
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Total Dermatology | Birmingham, Alabama, United States | — |
| Cahaba Dermatology Skin Health Center | Hoover, Alabama, United States | — |
| Medical Dermatology Specialists | Phoenix, Arizona, United States | — |
| Noble Clinical Research | Tucson, Arizona, United States | — |
| Johnson Dermatology Clinic | Fort Smith, Arkansas, United States | — |
| Burke Pharmaceutical Research | Hot Springs, Arkansas, United States | — |
| Zenith Research, Inc. | Beverly Hills, California, United States | — |
| UNISON Clinical Trials (Shahram Jacobs md inc.) | Encino, California, United States | — |
| First OC Dermatology Research Inc. | Fountain Valley, California, United States | — |
| Long Beach Research Institute, LLC | Long Beach, California, United States | — |
| Metropolis Dermatology Downtown LA - Probity - PPDS | Los Angeles, California, United States | — |
| Northridge Clinical Trials | Northridge, California, United States | — |
+ 205 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06108544